Evidence map›Paper›PMID 25781951›Full record

ArticlePloS one2015

Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease.

Bruna Gigante, Rona J Strawbridge, Ilais Moreno Velasquez, Zahra Golabkesh, Angela Silveira, Anuj Goel, Damiano Baldassarre, Fabrizio Veglia, Elena Tremoli, Robert Clarke and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Interactions betweenOncotarget · 2017
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Bruna GiganteUnit of Cardiovascular Epidemiology, Institute of Environmental Medicine (IMM), Stockholm, Sweden; Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd University Hospital, Stockholm, Sweden.
Rona J StrawbridgeCardiovascular Genetics and Genomics Group, Atherosclerosis Research Unit, Department of Medicine Solna, all at Karolinska Institutet, Stockholm, Sweden.
Ilais Moreno VelasquezUnit of Cardiovascular Epidemiology, Institute of Environmental Medicine (IMM), Stockholm, Sweden.
Zahra GolabkeshUnit of Cardiovascular Epidemiology, Institute of Environmental Medicine (IMM), Stockholm, Sweden.
Angela SilveiraCardiovascular Genetics and Genomics Group, Atherosclerosis Research Unit, Department of Medicine Solna, all at Karolinska Institutet, Stockholm, Sweden.
Anuj GoelDepartment of Cardiovascular Medicine, The Wellcome Trust Centre of Human Genetics, University of Oxford, Oxford, United Kingdom.
Damiano BaldassarreDipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy; Centro Cardiologico Monzino, IRCCS, Milan Italy.
Fabrizio VegliaDipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy.
Elena TremoliDipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy; Centro Cardiologico Monzino, IRCCS, Milan Italy.
Robert ClarkeClinical Trial Service Unit, University of Oxford, Oxford, United Kingdom.
Hugh WatkinsDepartment of Cardiovascular Medicine, The Wellcome Trust Centre of Human Genetics, University of Oxford, Oxford, United Kingdom.
Anders HamstenCardiovascular Genetics and Genomics Group, Atherosclerosis Research Unit, Department of Medicine Solna, all at Karolinska Institutet, Stockholm, Sweden; Dept of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Steve E HumphriesCentre for Cardiovascular Genetics, University College London, United Kingdom.
Ulf de FaireUnit of Cardiovascular Epidemiology, Institute of Environmental Medicine (IMM), Stockholm, Sweden; Dept of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Marine Environmental Analysis (Sweden) · SEUniversity of Milan · ITUniversity of Oxford · GBKarolinska Institutet · SEKarolinska University Hospital · SEUniversity College London · GB

Funding

British Heart Foundation RG/08/008/25291British Heart Foundation RG2008/014British Heart Foundation RG2008/08Wellcome TrustWellcome Trust 075491/Z/04
6 · The paper itself

Abstract

Variants at the interleukin 6 receptor (IL6R) gene regulate inflammation and are associated with risk of coronary heart disease (CHD). The aim of the present study was to investigate the effects of IL6R haplotypes on circulating levels of inflammatory biomarkers and risk of CHD. We performed a discovery analysis in SHEEP, a myocardial infarction (MI) case control study (n = 2,774) and replicated our results in two large, independent European populations, PROCARDIS, a CHD case control study (n = 7,998), and IMPROVE (n = 3,711) a prospective cardiovascular cohort study. Two major haplotype blocks (rs12083537A/G and rs4075015A/T--block 1; and rs8192282G/A, rs4553185T/C, rs8192284A/C, rs4240872T/C and rs7514452T/C--block 2) were identified in the IL6R gene. IL6R haplotype associations with C-reactive protein (CRP), fibrinogen, IL6, soluble IL6R (sIL6R), IL6, IL8 and TNF-α in SHEEP, CRP and fibrinogen in PROCARDIS and CRP in IMPROVE as well as association with risk of MI and CHD, were analyzed by THESIAS. Haplotypes in block 1 were associated neither with circulating inflammatory biomarkers nor with the MI/CHD risk. Haplotypes in block 2 were associated with circulating levels of CRP, in all three study populations, with fibrinogen in SHEEP and PROCARDIS, with IL8 and sIL6Rin SHEEP and with a modest, non significant, increase (7%) in MI/CHD risk in the three populations studied. Our results indicate that IL6R haplotypes regulate the circulating levels of inflammatory biomarkers. Lack of association with the risk of CHD may be explained by the combined effect of SNPs with opposite effect on the CHD risk, the sample size as well as by structural changes affecting sIL6R stability in the circulation.

Indexed as

HaplotypesAgedBiomarkersCase-Control StudiesCoronary DiseaseC-Reactive ProteinFemaleFibrinogenHumansInterleukin-8MaleMiddle AgedPolymorphism, Single NucleotideReceptors, Interleukin-6Tumor Necrosis Factor-alphaBiomarkersC-Reactive ProteinFibrinogenIL6R protein, humanInterleukin-8Receptors, Interleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID25781951
PMCPMC4364007
OpenAlexW1984931907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.